Hunho Song
Overview
Explore the profile of Hunho Song including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
85
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim S, Kim B, Kim I, Kim J, Kim H, Ryu H, et al.
J Cancer
. 2022 Mar;
13(4):1363-1369.
PMID: 35281880
GV1001 is a human telomerase peptide vaccine that induces a CD4/CD8 T-cell response against cancer cells, thereby affording an immunological anti-tumor effect. Here, we evaluated the efficacy and safety of...
2.
Han B, Kim B, Kim H, Choi D, Shim B, Lee K, et al.
J Cancer
. 2021 Jan;
12(3):912-917.
PMID: 33403047
We evaluated the efficacy and safety of gemcitabine in combination with erlotinib and S-1 for the treatment of advanced pancreatic cancer. Chemotherapy-naïve patients with pathologically-proven locally advanced, recurrent, or metastatic...
3.
Kang J, Kwon J, Lee Y, Park K, An H, Sohn J, et al.
Cancer Res Treat
. 2020 Mar;
52(3):907-916.
PMID: 32192275
Purpose: The purpose of this study was to compare ramosetron (RAM), aprepitant (APR), and dexamethasone (DEX) [RAD] with palonosetron (PAL), APR, and DEX [PAD] in controlling highly-emetogenic chemotherapy (HEC)-induced nausea...
4.
Bae W, Lee H, Park S, Kim J, Kim H, Maeng C, et al.
Cancer Med
. 2019 Jul;
8(12):5431-5437.
PMID: 31353788
The regional lymph node-positive bladder cancer was classified as stage IV in the AJCC 7th edition but was changed to stage IIIB in the 8th edition, revised in 2018. Among...
5.
Han B, Jung J, Kim H, Cho J, Kim K, Lim H, et al.
Cancer Chemother Pharmacol
. 2016 Sep;
78(5):949-958.
PMID: 27628195
Purposes: To determine the maximum tolerated dose (MTD), recommended dose (RD), and activity of combined oxaliplatin, irinotecan, and S-1 chemotherapy for metastatic or recurrent gastrointestinal (GI) cancer. Methods: Oxaliplatin and...
6.
Jung J, Ryu M, Ryoo B, Han B, Cho J, Lim M, et al.
Gastroenterol Res Pract
. 2016 Feb;
2016:6857625.
PMID: 26839542
Background. This retrospective study aimed to assess the efficacy and toxicities of second-line chemotherapy with irinotecan, leucovorin, and 5-fluorouracil (5-FU) in metastatic gastric cancer (MGC) patients previously treated with docetaxel...
7.
Phase II study of docetaxel, oxaliplatin, and S-1 therapy in patients with metastatic gastric cancer
Kim H, Ryu M, Zang D, Ryoo B, Yang D, Cho J, et al.
Gastric Cancer
. 2015 May;
19(2):579-585.
PMID: 25997815
Background: Although the docetaxel, 5-fluorouracil, and cisplatin triplet has yielded significant improvements in time to progression, overall survival, and overall response rate, the high incidence of severe adverse events limits...
8.
Kim H, Kim H, Zang D, Oh H, Jeon J, Cho J, et al.
Cancer Chemother Pharmacol
. 2015 Jan;
75(4):711-8.
PMID: 25630414
Purpose: A phase II study was conducted to evaluate the efficacy and safety of gemcitabine and S-1 combination chemotherapy in patients with metastatic biliary tract cancer (BTC). Methods: Patients with...
9.
Park K, Jang G, Baek S, Song H
Tumori
. 2014 May;
100(2):201-6.
PMID: 24852866
Aims And Background: The aim of this study was to evaluate the value of positron emission tomography/computed tomography (PET/CT) for preoperative staging of gastric cancer and to compare the diagnostic...
10.
Song H, Han B, Park C, Kim J, Jeon J, Kim I, et al.
Cancer Chemother Pharmacol
. 2013 Aug;
72(4):845-52.
PMID: 23978987
Purpose: To evaluate the efficacy and safety of combined gemcitabine and S-1 as first-line chemotherapy for patients with locally advanced or metastatic pancreatic cancer. Methods: This study included patients who...